The key to finding new and better treatments for cancer lies in research. The Huntsman Cancer Institute (HCI) Clinical Trials Office (CTO) continually develops new approaches to help cancer patients live longer and better lives. Patient participation in clinical trials is an essential factor in this process.
All cancer treatments used today began with research that became clinical trials. Clinical trials test treatments for safety and effectiveness in patients, playing an important role in advancing cancer research from the laboratory to the development of new cancer treatments. Learn more about clinical trials by selecting a topic below.
ABOUT THE CLINICAL TRIALS OFFICE
The Huntsman Cancer Institute (HCI) Clinical Trials Office (CTO) centrally administers the implementation and conduct of internally and externally funded adult oncology studies. It works collaboratively with the Primary Children’s Medical Center Pediatric Trials Office, which is also located on the University of Utah (U of U) campus, on studies of cancers involving children. The CTO has a large portfolio of cancer-related studies, including research focused on treatment, behavior, prevention, imaging, diagnostics, genetics, and supportive care. All adult clinical research activities in oncology are managed under this single reporting structure thus ensuring uniformity and consistency.
Streamline study activation; promote completion of meritorious studies
Assure study integrity and patient safety
Increase accrual by expanding to a larger research network
The HCI CTO is a centralized office composed of well-trained clinical management, data management, regulatory, and financial staff members who promote uniformity and consistency in clinical research by providing support for principal investigators and patients. CTO staff have regular assignments with HCI’s Multidisciplinary Disease Groups (MDGs), allowing them to build expertise in a particular area of oncology.
Senior Director of Clinical Research: Sunil Sharma, MD
Training and Mentorship Manager: Rachel Kingsford, MS, CCRP
Director of Research Compliance: Jennifer Katz, BS, CCRP
In the event a researcher intends to provide information or materials (Materials) restricted under applicable export control law or regulations (http://osp.utah.edu/policies/export-controls.php) to the Huntsman Cancer Institute Clinical Trial Office (CTO) for processing, the researcher must first notify the CTO of its intention to provide Material at least 7 days in advance of actually providing Material, and indicate to whom the Material is being provided, along with specific reference to the applicable regulatory sections. The CTO will then determine whether it will accept such Material or decline. In addition, researcher access to CTO services is subject to compliance with all U.S. export control and Office of Foreign Assets Controls (OFAC) regulations.
Huntsman Cancer Institute 2000 Circle of Hope Salt Lake City, UT 84112